A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice
In: Frontiers in Microbiology, Jg. 14 (2023-03-01)
Online
academicJournal
Zugriff:
Toxoplasma gondii (T. gondii) can infect almost all warm-blooded animals and is a major threat to global public health. Currently, there is no effective drug or vaccine for T. gondii. In this study, bioinformatics analysis on B and T cell epitopes revealed that TGGT1_316290 (TG290) had superior effects compared with the surface antigen 1 (SAG1). TG290 mRNA-LNP was constructed through the Lipid Nanoparticle (LNP) technology and intramuscularly injected into the BALB/c mice, and its immunogenicity and efficacy were explored. Analysis of antibodies, cytokines (IFN-γ, IL-12, IL-4, and IL-10), lymphocytes proliferation, cytotoxic T lymphocyte activity, dendritic cell (DC) maturation, as well as CD4+ and CD8+ T lymphocytes revealed that TG290 mRNA-LNP induced humoral and cellular immune responses in vaccinated mice. Furthermore, T-Box 21 (T-bet), nuclear factor kappa B (NF-kB) p65, and interferon regulatory factor 8 (IRF8) subunit were over-expressed in the TG290 mRNA-LNP-immunized group. The survival time of mice injected with TG290 mRNA-LNP was significantly longer (18.7 ± 3 days) compared with the survival of mice of the control groups (p
Titel: |
A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice
|
---|---|
Autor/in / Beteiligte Person: | Li, Dan ; Zhang, Yizhuo ; Li, Shiyu ; Zheng, Bin |
Link: | |
Zeitschrift: | Frontiers in Microbiology, Jg. 14 (2023-03-01) |
Veröffentlichung: | Frontiers Media S.A., 2023 |
Medientyp: | academicJournal |
ISSN: | 1664-302X (print) |
DOI: | 10.3389/fmicb.2023.1145114 |
Schlagwort: |
|
Sonstiges: |
|